[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-379168-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-379168-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","natural-and-synthetic-anticancer-epidrugs-targeting-the-epigenetic-integrator-uhrf1","Natural and Synthetic Anticancer Epidrugs Targeting the Epigenetic Integrator UHRF1","","Cancer remains a leading cause of death globally, with rising incidence and mortality despite advances in therapy. Genetic and epigenetic dysregulation drives cellular transformation and tumorigenesis, while the multidomain epigenetic regulator UHRF1 is frequently overexpressed and contributes to oncogenic signaling. By coordinating DNA methylation and histone modifications, UHRF1 silences tumor-suppressor genes, supports drug resistance, and promotes apoptosis escape. This review summarizes mechanisms and evaluates natural and synthetic epidrugs that inhibit UHRF1 activity and/or expression.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/natural-and-synthetic-anticancer-epidrugs-targeting-the-epigenetic-integrator-uhrf1/379168/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/natural-and-synthetic-anticancer-epidrugs-targeting-the-epigenetic-integrator-uhrf1/379168.png","ImageObject",300,407,{"name":42,"@type":43},"นรินทร์","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-26","2026-09-24",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",14,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why is UHRF1 considered an important target in cancer therapy?","Question",{"text":63,"@type":64},"UHRF1 is a multidomain epigenetic regulator that coordinates DNA methylation and histone modifications. Its overexpression supports tumor-suppressor gene silencing and contributes to drug resistance and apoptosis escape.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What roles do epigenetic mechanisms play in cancer development?",{"text":68,"@type":64},"Epigenetic alterations drive heritable changes in gene function without modifying DNA sequence, shifting the balance toward oncogenes and promoting proliferation. The review highlights DNA methylation, histone modifications, and non-coding RNA regulation as key mechanisms.",{"name":70,"@type":61,"acceptedAnswer":71},"How do natural and synthetic epidrugs affect UHRF1-related oncogenic activity?",{"text":72,"@type":64},"Downregulating UHRF1 using natural compounds can reactivate tumor-suppressor genes, inhibit cell growth, and promote apoptosis. The review also discusses potential natural and synthetic compounds designed to inhibit UHRF1 activity and/or its expression.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},379168,1790524905,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":108,"slug":109},7,40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":113,"slug":114},8,"Research & Report",30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":107,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146},2336475104957,"https://ap-avatar.wpscdn.com/avatar/22000c4c6bd8a5076e1?x-image-process=image/resize,m_fixed,w_180,h_180&k=1787554080175789136","molecules   \nReview  \nNatural and Synthetic Anticancer Epidrugs Targeting the Epigenetic Integrator UHRF1  \nWaseem Ashraf 1,†, Tanveer Ahmad 2,†, Nicolas Reynoird 2, Ali Hamiche 3, Yves M²ly 4, Christian Bronner 3, * and Marc Mousli 4, *  \nCitation: Ashraf, W.; Ahmad, T.; Reynoird, N.; Hamiche, A.; Mély, Y.; Bronner, C.; Mousli, M. Natural and Synthetic Anticancer Epidrugs Targeting the Epigenetic Integrator UHRF1 . Molecules 2023, 28, 5997 . [https://doi.org/10.3390/](https://doi.org/10.3390/)[ ](https://doi.org/10.3390/)molecules28165997  \nAcademic Editor: Carlotta Granchi  \nReceived: 21 June 2023  \nRevised: 6 August 2023  \nAccepted: 8 August 2023  \nPublished: 10 August 2023  \nCopyright: © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \n1 Department of Pharmacology, Faculty of Pharmacy, Bahauddin Zakariya University, Multan 60800, Pakistan; [waseem.ashraf@bzu.edu.pk](waseem.ashraf@bzu.edu.pk)  \n2 Institut Pour L'avanc²e des Biosciences, Centre de Recherche UGA, INSERM U1209, CNRS 5309, Universit² Grenoble Alpes, 38058 Grenoble, France; [tanveer.ahmad@univ-grenoble-alpes.fr](tanveer.ahmad@univ-grenoble-alpes.fr) (T.A.); [nicolas.reynoird@univ-grenoble-alpes.fr](nicolas.reynoird@univ-grenoble-alpes.fr) (N.R.)  \n3 Department of Functional Genomics, Institut de G²n²tique et de Biologie Mol²culaire et Cellulaire (IGBMC), INSERM U1258, CNRS UMR 7104, Universit² de Strasbourg, Equipe Labellis²e Ligue Contre le Cancer, 67401 Illkirch, France; [ali.hamiche@igbmc.fr](ali.hamiche@igbmc.fr)  \n4 Laboratoire de Bioimagerie et Pathologies, UMR 7021 CNRS, Facult² de Pharmacie, Universit² de Strasbourg, 67401 Illkirch, France; [yves.mely@unistra.fr](yves.mely@unistra.fr)  \n* [Correspondence: bronnerc@igbmc.fr](Correspondence: bronnerc@igbmc.fr) (C.B.); [marc.mousli@unistra.fr](marc.mousli@unistra.fr) (M.M.); Tel.: +33-3-68-85-42-49 (M.M.)† These authors contributed equally to this work.  \nAbstract: Cancer is one of the leading causes of death worldwide, and its incidence and mortality are increasing each year. Improved therapeutic strategies against cancer have progressed, but remain insufficient to invert this trend. Along with several other risk factors, abnormal genetic and epigenetic regulations play a critical role in the initiation of cellular transformation, as well as tumorigenesis. The epigenetic regulator UHRF1 (ubiquitin-like, containing PHD and RING finger domains 1) is a multidomain protein with oncogenic abilities overexpressed in most cancers. Through the coordination of its multiple domains and other epigenetic key players, UHRF1 regulates DNA methylation and histone modifications. This well-coordinated dialogue leads to the silencing of tumor-suppressor genes (TSGs) and facilitates tumor cells' resistance toward anticancer drugs, ultimately promoting apoptosis escape and uncontrolled proliferation. Several studies have shown that the downregulation of UHRF1 with natural compounds in tumor cells induces the reactivation of various TSGs, inhibits cell growth, and promotes apoptosis. In this review, we discuss the underlying mechanisms and the potential of various natural and synthetic compounds that can inhibit/minimize UHRF1's oncogenic activities and/or its expression.  \nKeywords: cancer; DNA methylation; epidrugs; epigenetics; phytochemical; tumor-suppressor genes UHRF1  \n1. Introduction  \nCancer is the second leading cause of death after cardiovascular pathologies. The incidence of cancer is increasing in both developing and developed countries, and approximately 10 million people died of this deadly disease in 2018 [1] . The increased prevalence of cancer is often correlated with hereditary traits, environmental pollution, bad life","cbCaidhtjosGplxo","https://ap.wps.com/l/cbCaidhtjosGplxo","pdf",1412471,26,"English","# Introduction\n# Structure and Function of UHRF1\n## Structure of UHRF1","[{\"question\":\"Why is UHRF1 considered an important target in cancer therapy?\",\"answer\":\"UHRF1 is a multidomain epigenetic regulator that coordinates DNA methylation and histone modifications. Its overexpression supports tumor-suppressor gene silencing and contributes to drug resistance and apoptosis escape.\"},{\"question\":\"What roles do epigenetic mechanisms play in cancer development?\",\"answer\":\"Epigenetic alterations drive heritable changes in gene function without modifying DNA sequence, shifting the balance toward oncogenes and promoting proliferation. The review highlights DNA methylation, histone modifications, and non-coding RNA regulation as key mechanisms.\"},{\"question\":\"How do natural and synthetic epidrugs affect UHRF1-related oncogenic activity?\",\"answer\":\"Downregulating UHRF1 using natural compounds can reactivate tumor-suppressor genes, inhibit cell growth, and promote apoptosis. The review also discusses potential natural and synthetic compounds designed to inhibit UHRF1 activity and/or its expression.\"}]","Natural and Synthetic Anticancer Epidrugs Targeting the Epigenetic Integrator UHRF1 | PDF",1790234410,66]